Persistent ER stress causes GPI anchor deficit to convert a GPI-anchored prion protein into pro-PrP via the ATF6-miR449c-5p-PIGV axis.
Persistent ER stress causes GPI anchor deficit to convert a GPI-anchored prion protein into pro-PrP via the ATF6-miR449c-5p-PIGV axis.
复制标题
DOI:
10.1016/j.jbc.2023.104982
复制
发表时间:
2023-08
影响因子:
4.8
通讯作者:
Li, Chaoyang
中科院分区:
文献类型:
--
作者:
Li, JingFeng;Li, SaSa;Yu, ShuPei;Yang, Jie;Ke, JingRu;Li, Huan;Chen, Heng;Lu, MingJian;Sy, Man-Sun;Gao, ZhenXing;Li, Chaoyang
Endoplasmic reticulum (ER) stress and unfolded protein response are cells’ survival strategies to thwart disruption of proteostasis. Tumor cells are continuously being challenged by ER stress. The prion protein, PrP, normally a glycosylphosphatidylinositol (GPI)-anchored protein exists as a pro-PrP retaining its GPI-peptide signal sequence in human pancreatic ductal cell adenocarcinoma (PDAC). Higher abundance of pro-PrP indicates poorer prognosis in PDAC patients. The reason why PDAC cells express pro-PrP is unknown. Here, we report that persistent ER stress causes conversion of GPI-anchored PrP to pro-PrP via a conserved ATF6–miRNA449c-5p–PIGV axis. Mouse neurons and AsPC-1, a PDAC cell line, express GPI-anchored PrP. However, continuous culture of these cells with the ER stress inducers thapsigargin or brefeldin A results in the conversion of a GPI-anchored PrP to pro-PrP. Such a conversion is reversible; removal of the inducers allows the cells to re-express a GPI-anchored PrP. Mechanistically, persistent ER stress increases the abundance of an active ATF6, which increases the level of miRNA449c-5p (miR449c-5p). By binding the mRNA of PIGV at its 3′-UTRs, miR449c-5p suppresses the level of PIGV, a mannosyltransferase pivotal in the synthesis of the GPI anchor. Reduction of PIGV leads to disruption of the GPI anchor assembly, causing pro-PrP accumulation and enhancing cancer cell migration and invasion. The importance of ATF6–miR449c-5p–PIGV axis is recapitulated in PDAC biopsies as the higher levels of ATF6 and miR449c-5p and lower levels of PIGV are markers of poorer outcome for patients with PDAC. Drugs targeting this axis may prevent PDAC progression.
登录
查看更多内容
影响因子:
6.6
作者:
Atkinson, Caroline J.;Kawamata, Futoshi;Wiegmans, Adrian P.
通讯作者:
Wiegmans, Adrian P.
影响因子:
5
作者:
Belmont PJ;Chen WJ;Thuerauf DJ;Glembotski CC
通讯作者:
Glembotski CC
DOI:
10.1073/pnas.85.13.4657
发表时间:
1988-07-01
影响因子:
11.1
作者:
CAUGHEY, B;RACE, RE;CHESEBRO, B
通讯作者:
CHESEBRO, B
影响因子:
--
作者:
Corsaro A;Bajetto A;Thellung S;Begani G;Villa V;Nizzari M;Pattarozzi A;Solari A;Gatti M;Pagano A;Würth R;Daga A;Barbieri F;Florio T
通讯作者:
Florio T
DOI:
10.1038/s41568-020-00312-2
发表时间:
2021-03
期刊:
Nature reviews. Cancer
影响因子:
--
作者:
Chen X;Cubillos-Ruiz JR
通讯作者:
Cubillos-Ruiz JR